Maxime Verhoeven

127 Effectiveness and safety of treat-to-target strategies over 5 years Supplementary Table S5 (continued) Period Strategy comparisons Mean differences 95%CI of mean differences P-value 4 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ 0.17 0.28 -0.11 -0.33 to 0.67 -0.22 to 0.78 -0.60 to 0.38 0.50 0.27 0.66 5 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ 0.19 0.29 -0.11 -0.32 to 0.69 -0.21 to 0.80 -0.60 to 0.39 0.47 0.25 0.68 Change in √SJC28 between initial treatment strategy groups at the end of every year (n=226) 1 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ -0.31 -0.16 -0.15 -0.43 to -0.18 -0.29 to -0.03 -0.27 to -0.02 <0.01 0.01 0.02 2 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ -0.26 -0.13 -0.12 -0.37 to -0.14 -0.25 to -0.01 -0.12 to 0.14 <0.01 0.03 0.04 3 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ 0.05 0.04 0.01 -0.08 to 0.18 -0.09 to 0.17 -0.12 to 0.14 0.46 0.58 0.85 4 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ 0.06 0.04 0.02 -0.08 to 0.19 -0.09 to 0.17 -0.11 to 0.15 0.40 0.54 0.81 5 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ 0.06 0.05 0.02 -0.07 to 0.20 -0.09 to 0.18 -0.11 to 0.15 0.35 0.51 0.77 Change in √TJC28 between initial treatment strategy groups at the end of every year (n=226) 1 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ -0.24 -0.17 -0.07 -0.51 to -0.08 -0.33 to -0.01 -0.24 to 0.09 <0.01 0.04 0.37 2 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ -0.21 -0.15 -0.06 -0.37 to -0.05 -0.31 to 0.01 -0.21 to 0.10 <0.01 0.06 0.46 3 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ -0.01 -0.04 0.03 -0.20 to 0.18 -0.23 to 0.15 -0.16 to 0.22 0.93 0.70 0.76 4 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ -0.00 -0.03 0.03 -0.20 to 0.19 -0.23 to 0.16 -0.16 to 0.22 0.98 0.72 0.74 5 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ 0.00 -0.03 0.03 -0.19 to 0.20 -0.22 to 0.16 -0.16 to 0.22 0.98 0.75 0.72 The treatment strategy groups are according to the initial randomisation at start of U-Act-Early. All analyses were corrected for baseline DAS28 category (DAS28 <5.1 or ≥5.1) and centre. Outcomes are based on mixed model analyses with random intercept for repeated measurements, and fixed effects for treatment arm, visit-week, interaction visit-week*treatment arm. TCZ+MTX= tocilizumab + methotrexate initiation strategy group; TCZ= tocilizumab + placebo-methotrexate initiation strategy group; MTX= methotrexate + placebo-tocilizumab initiation strategy group; 95%CI= 95 percent confidence interval; DAS28= disease activity score assessing 28 joints; VAS= visual analogue scale; SJC= swollen joint count; TJC= tender joint count. 6